Haloperidol Blood Levels and Clinical Effects

Jan Volavka, Thomas Cooper, P. Czobor, I. Bitter, Morris Meisner, Eugene Laska, Pedro Gastanaga, Menahem Krakowski, Martha Crowner, Richard Douyon

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

This study explored the relationships between plasma levels and the clinical effects of haloperidol in 176 acutely exacerbated schizophrenic or schizoaffective patients. After a single-blind placebo period of 1 week (period 1), they entered the double-blind period 2 randomly assigned to one of three plasma levels of haloperidol: low (2 to 13 ng/mL), medium (13.1 to 24 ng/mL), or high (24.1 to 35 ng/mL). Patients whose conditions did not improve in period 2 continued on one of the three haloperidol levels (period 3). Periods 2 and 3 lasted 6 weeks each. Only minor differences in clinical responses were noted among the three levels of haloperidol. These results imply that low or moderate doses of neuroleptics are appropriate for many acutely psychotic patients.

Original languageEnglish
Pages (from-to)354-361
Number of pages8
JournalArchives of General Psychiatry
Volume49
Issue number5
DOIs
Publication statusPublished - 1992

Fingerprint

Haloperidol
Antipsychotic Agents
Placebos
Blood
Plasma

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Haloperidol Blood Levels and Clinical Effects. / Volavka, Jan; Cooper, Thomas; Czobor, P.; Bitter, I.; Meisner, Morris; Laska, Eugene; Gastanaga, Pedro; Krakowski, Menahem; Crowner, Martha; Douyon, Richard.

In: Archives of General Psychiatry, Vol. 49, No. 5, 1992, p. 354-361.

Research output: Contribution to journalArticle

Volavka, J, Cooper, T, Czobor, P, Bitter, I, Meisner, M, Laska, E, Gastanaga, P, Krakowski, M, Crowner, M & Douyon, R 1992, 'Haloperidol Blood Levels and Clinical Effects', Archives of General Psychiatry, vol. 49, no. 5, pp. 354-361. https://doi.org/10.1001/archpsyc.1992.01820050018002
Volavka, Jan ; Cooper, Thomas ; Czobor, P. ; Bitter, I. ; Meisner, Morris ; Laska, Eugene ; Gastanaga, Pedro ; Krakowski, Menahem ; Crowner, Martha ; Douyon, Richard. / Haloperidol Blood Levels and Clinical Effects. In: Archives of General Psychiatry. 1992 ; Vol. 49, No. 5. pp. 354-361.
@article{b81d9fc3db764720aa1b9c2c04a014e0,
title = "Haloperidol Blood Levels and Clinical Effects",
abstract = "This study explored the relationships between plasma levels and the clinical effects of haloperidol in 176 acutely exacerbated schizophrenic or schizoaffective patients. After a single-blind placebo period of 1 week (period 1), they entered the double-blind period 2 randomly assigned to one of three plasma levels of haloperidol: low (2 to 13 ng/mL), medium (13.1 to 24 ng/mL), or high (24.1 to 35 ng/mL). Patients whose conditions did not improve in period 2 continued on one of the three haloperidol levels (period 3). Periods 2 and 3 lasted 6 weeks each. Only minor differences in clinical responses were noted among the three levels of haloperidol. These results imply that low or moderate doses of neuroleptics are appropriate for many acutely psychotic patients.",
author = "Jan Volavka and Thomas Cooper and P. Czobor and I. Bitter and Morris Meisner and Eugene Laska and Pedro Gastanaga and Menahem Krakowski and Martha Crowner and Richard Douyon",
year = "1992",
doi = "10.1001/archpsyc.1992.01820050018002",
language = "English",
volume = "49",
pages = "354--361",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Haloperidol Blood Levels and Clinical Effects

AU - Volavka, Jan

AU - Cooper, Thomas

AU - Czobor, P.

AU - Bitter, I.

AU - Meisner, Morris

AU - Laska, Eugene

AU - Gastanaga, Pedro

AU - Krakowski, Menahem

AU - Crowner, Martha

AU - Douyon, Richard

PY - 1992

Y1 - 1992

N2 - This study explored the relationships between plasma levels and the clinical effects of haloperidol in 176 acutely exacerbated schizophrenic or schizoaffective patients. After a single-blind placebo period of 1 week (period 1), they entered the double-blind period 2 randomly assigned to one of three plasma levels of haloperidol: low (2 to 13 ng/mL), medium (13.1 to 24 ng/mL), or high (24.1 to 35 ng/mL). Patients whose conditions did not improve in period 2 continued on one of the three haloperidol levels (period 3). Periods 2 and 3 lasted 6 weeks each. Only minor differences in clinical responses were noted among the three levels of haloperidol. These results imply that low or moderate doses of neuroleptics are appropriate for many acutely psychotic patients.

AB - This study explored the relationships between plasma levels and the clinical effects of haloperidol in 176 acutely exacerbated schizophrenic or schizoaffective patients. After a single-blind placebo period of 1 week (period 1), they entered the double-blind period 2 randomly assigned to one of three plasma levels of haloperidol: low (2 to 13 ng/mL), medium (13.1 to 24 ng/mL), or high (24.1 to 35 ng/mL). Patients whose conditions did not improve in period 2 continued on one of the three haloperidol levels (period 3). Periods 2 and 3 lasted 6 weeks each. Only minor differences in clinical responses were noted among the three levels of haloperidol. These results imply that low or moderate doses of neuroleptics are appropriate for many acutely psychotic patients.

UR - http://www.scopus.com/inward/record.url?scp=0026643073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026643073&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1992.01820050018002

DO - 10.1001/archpsyc.1992.01820050018002

M3 - Article

VL - 49

SP - 354

EP - 361

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 5

ER -